Around one-third of patients tolerate full servings of their allergens with omalizumab

Among patients with multiple food allergies treated with omalizumab, 36% achieved a cumulative tolerated dose of at least 4,044 mg for three foods by the end of treatment, according to results published in JAMA Pediatrics.Compared with patients receiving omalizumab-facilitated multiallergen oral immunotherapy (MOIT), a greater or similar proportion of patients receiving omalizumab reached this